Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 23 November 2022
Irreversible electroporation for treating prostate cancerStatus:Awaiting developmentProgramme:Interventional procedures guidanceExpected publication date: 1 February 2023
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancerStatus:Awaiting developmentProgramme:Interventional procedures guidanceExpected publication date: 7 February 2023
Focal therapy using high-intensity focused ultrasound for localised prostate cancerStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: 5 April 2023
MRI fusion biopsy in people with suspected prostate cancerStatus:In developmentProgramme:Diagnostics guidanceExpected publication date: 17 May 2023
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer [ID3971]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 24 May 2023
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 11 October 2023
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Transperineal biopsy for diagnosing prostate cancerStatus:In developmentProgramme:Diagnostics guidanceExpected publication date: TBC
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID 5103]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Prostate specific membrane antigen (PSMA) radiotherapy for treating advanced prostate cancerStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC